EMA人用医药产品委员会:万达生物制药的伊洛哌酮获负面意见 用于精神分裂症治疗

美股速递
Feb 27

欧洲药品管理局人用医药产品委员会对万达生物制药旗下药物伊洛哌酮治疗精神分裂症的申请出具了否定性评估意见。该决定意味着该药物现阶段未获得委员会推荐批准。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10